1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015, 136(5):E359-E386.
2. Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P, Pradier O, Hatt M, Schick U: Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018, 45(5):768-786.
3. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Jr., Clarke-Pearson DL, Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999, 17(5):1339-1348.
4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999, 340(15):1137-1143.
5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999, 340(15):1144-1153.
6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, 3rd, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999, 340(15):1154-1161.
7. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Jr., Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18(8):1606-1613.
8. Thomas GM: Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med 1999, 340(15):1198-1200.
9. Kumar L, Gupta S: Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal. Oncology 2016, 91 Suppl 1:8-17.
10. Lucia F, Visvikis D, Vallières M, Desseroit MC, Miranda O, Robin P, Bonaffini PA, Alfieri J, Masson I, Mervoyer A et al: External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2019, 46(4):864-877.
11. Herrera FG, Prior JO: The role of PET/CT in cervical cancer. Front Oncol 2013, 3:34.
12. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J et al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37(1):181-200.
13. Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I: Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging 2013, 40(12):1836-1842.
14. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY: Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014, 41(1):50-58.
15. Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJ: The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging 2014, 41(2):276-282.
16. Maffione AM, Ferretti A, Grassetto G, Bellan E, Capirci C, Chondrogiannis S, Gava M, Marzola MC, Rampin L, Bondesan C et al: Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging 2013, 40(6):853-864.
17. Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY: Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imaging 2014, 41(3):452-461.
18. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50 Suppl 1(Suppl 1):122S-150S.
19. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35(13):1773-1782.
20. Han S, Kim H, Kim YJ, Suh CH, Woo S: Prognostic Value of Volume-Based Metabolic Parameters of (18)F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2018, 211(5):1112-1121.
21. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
22. Gerlinger M, Swanton C: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103(8):1139-1143.
23. Ha S, Choi H, Paeng JC, Cheon GJ: Radiomics in Oncological PET/CT: a Methodological Overview. Nucl Med Mol Imaging 2019, 53(1):14-29.
24. Chung HH, Kang SY, Ha S, Kim JW, Park NH, Song YS, Cheon GJ: Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. J Gynecol Oncol 2016, 27(2):e15.
25. Guan Y, Li W, Jiang Z, Chen Y, Liu S, He J, Zhou Z, Ge Y: Whole-Lesion Apparent Diffusion Coefficient-Based Entropy-Related Parameters for Characterizing Cervical Cancers: Initial Findings. Acad Radiol 2016, 23(12):1559-1567.
26. Ho KC, Fang YH, Chung HW, Yen TC, Ho TY, Chou HH, Hong JH, Huang YT, Wang CC, Lai CH: A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy. Am J Nucl Med Mol Imaging 2016, 6(3):166-175.
27. Reuzé S, Orlhac F, Chargari C, Nioche C, Limkin E, Riet F, Escande A, Haie-Meder C, Dercle L, Gouy S et al: Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners. Oncotarget 2017, 8(26):43169-43179.
28. Torheim T, Groendahl AR, Andersen EK, Lyng H, Malinen E, Kvaal K, Futsaether CM: Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients. Acta Oncol 2016, 55(11):1294-1298.
29. Yip SS, Aerts HJ: Applications and limitations of radiomics. Phys Med Biol 2016, 61(13):R150-166.
30. Chong GO, Lee WK, Jeong SY, Park SH, Lee YH, Lee SW, Hong DG, Kim JC, Lee YS: Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy. Oncotarget 2017, 8(52):90402-90412.
31. Chen SW, Shen WC, Hsieh TC, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, Yen KY, Kao CH: Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy. Sci Rep 2018, 8(1):11859.
32. Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, Pellot-Barakat C, Soussan M, Frouin F, Buvat I: LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res 2018, 78(16):4786-4789.
33. Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M: [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol 2016, 11:43.
34. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N et al: Assessment of Total Lesion Glycolysis by (18)F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 2017, 23(8):1981-1987.
35. Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, Wu N, Tian J, Gillies RJ: (18)F-FDG PET/CT Habitat Radiomics Predicts Outcome of Patients with Cervical Cancer Treated with Chemoradiotherapy. Radiol Artif Intell 2020, 2(6):e190218.
36. Esfahani SA, Torrado-Carvajal A, Amorim BJ, Groshar D, Domachevsky L, Bernstine H, Stein D, Gervais D, Catalano OA: PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features. Mol Imaging Biol 2021.
37. Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D: Characterization of PET/CT images using texture analysis: the past, the present… any future?Eur J Nucl Med Mol Imaging 2017, 44(1):151-165.
38. Altazi BA, Fernandez DC, Zhang GG, Hawkins S, Naqvi SM, Kim Y, Hunt D, Latifi K, Biagioli M, Venkat P et al: Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes. Phys Med 2018, 46:180-188.
39. Crandall J, Fraum T, Lee M-Y, Grigsby P, Wahl R: Repeatability of 18F-FDG PET radiomic features in pelvic malignancies. J Nucl Med 2020, 61 Suppl1(supplement 1):272.
40. Novikov M: Multiparametric quantitative and texture (18)F-FDG PET/CT analysis for primary malignant tumour grade differentiation. Eur Radiol Exp 2019, 3(1):48.
41. Sollini M, Cozzi L, Pepe G, Antunovic L, Lania A, Di Tommaso L, Magnoni P, Erba PA, Kirienko M: [(18)F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results. Eur J Hybrid Imaging 2017, 1(1):3.
42. Cegla P, Burchardt E, Roszak A, Czepczynski R, Kubiak A, Cholewinski W: Influence of Biological Parameters Assessed in [18F]FDG PET/CT on Overall Survival in Cervical Cancer Patients. Clin Nucl Med 2019, 44(11):860-863.
43. Rahman T, Tsujikawa T, Yamamoto M, Chino Y, Shinagawa A, Kurokawa T, Tsuchida T, Kimura H, Yoshida Y, Okazawa H: Different Prognostic Implications of 18F-FDG PET Between Histological Subtypes in Patients With Cervical Cancer. Medicine (Baltimore) 2016, 95(9):e3017.
44. Tsujikawa T, Rahman T, Yamamoto M, Yamada S, Tsuyoshi H, Kiyono Y, Kimura H, Yoshida Y, Okazawa H: (18)F-FDG PET radiomics approaches: comparing and clustering features in cervical cancer. Ann Nucl Med 2017, 31(9):678-685.